UBS Group
ALDX icon

UBS Group’s Aldeyra Therapeutics ALDX Stock Holding History

UBS Group’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20,000
Closed -$80K – 10186
2021
Q4 		$80K Buy
+20,000
New +$153K ﹤0.01% 6500

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group's ALDX Position: Q1 2026 in Review

UBS Group increased its Aldeyra Therapeutics (ALDX) stake by 462% in Q1 2026, buying an estimated $1.94M and bringing the position to 537,569 shares worth $908K. The position accounts for ﹤0.01% of the portfolio, ranked #5625.

UBS Group first reported a position in ALDX in Q1 2015 and has held it in 42 quarters since. The position peaked at $4.27M in Q1 2022. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • UBS Group held 537,569 shares of Aldeyra Therapeutics worth $908K as of Q1 2026.
  • UBS Group bought 441,892 Aldeyra Therapeutics shares in Q1 2026, an estimated $1.94M.
  • Aldeyra Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5625 holding.
  • UBS Group first reported a position in Aldeyra Therapeutics in Q1 2015 and has held it in 42 quarters since.
  • UBS Group's Aldeyra Therapeutics position peaked at $4.27M in Q1 2022.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.